{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.\n\nsodium thiosulfate: Given IV\n\nexamination: Patients undergo audiological assessments periodically","id":"OG000","title":"STS Arm (Sodium Thiosulfate Treatment)"},{"description":"Patients do not receive sodium thiosulfate.\n\nexamination: Patients undergo audiological assessments periodically","id":"OG001","title":"Observation Arm (No Sodium Thiosulfate Treatment)"}],"populationDescription":"Data was and never will be collected","reportingStatus":"POSTED","timeFrame":"4 weeks after the last dose of cisplatin","title":"Hearing Loss Among Patients Carrying/Not-carrying Two Key Gene Mutations (TPMT and COMT)","type":"SECONDARY"}